ABBVIE Business Summary

AbbVie Inc. (ABBV) is a global, research-based biopharmaceutical giant that generates revenue primarily through the discovery, development, and commercialization of advanced therapies across four core segments: Immunology, Neuroscience, Oncology, and Aesthetics. As of early 2026, the company has successfully navigated the patent expiration of its legacy blockbuster Humira by scaling its next-generation immunology assets, Skyrizi and Rinvoq, which are projected to contribute over $31 billion in combined revenue for the 2026 fiscal year. The company’s diversified portfolio also includes high-growth neuroscience products like Vraylar and the newly launched Parkinson’s therapy Vyalev, alongside a leading medical aesthetics franchise anchored by Botox Cosmetic. AbbVie maintains a top-tier market position, ranking among the world's three largest pharmaceutical firms by revenue, and competes directly with industry titans such as Johnson & Johnson, Merck & Co., Pfizer, and Amgen. Its competitive edge is defined by a high-density R&D pipeline and a strategic focus on complex therapeutic areas with high barriers to entry. Following its 2013 spin-off from Abbott Laboratories, AbbVie is currently led by Robert A. Michael, who serves as Chairman and Chief Executive Officer. Michael, a 30-year veteran of the Abbott/AbbVie ecosystem, succeeded founding CEO Richard A. Gonzalez and previously served as the company’s President and COO, where he was instrumental in the $63 billion acquisition of Allergan. The executive leadership team includes Scott T. Reents as Executive VP and Chief Financial Officer, and Dr. Roopal Thakkar as Executive VP of Research & Development and Chief Scientific Officer, who oversees a $100 billion ten-year capital investment commitment in U.S. innovation. The company’s governance is supported by a robust Board of Directors featuring notable figures such as Lead Independent Director Roxanne S. Austin (President of Austin Investment Advisors) and Frederick H. Waddell (former Chairman and CEO of Northern Trust), ensuring strong institutional oversight as the company targets a 9.5% operational sales growth rate in 2026.